>>>welcome visitor, haven't logged in. Login
Subscribe Now Contact us  
Font Size:  A A A Search “Fabao” Window English 中文 = 简体  繁体
  Favorite   DownLoad   Print
 
Measures for Compulsory License on Patent Implementation concerning Public Health Problems [Expired]
涉及公共健康问题的专利实施强制许可办法 [失效]
【法宝引证码】

 
Order of the State Intellectual Property Office 

国家知识产权局局令


(No.37)
 
(第37号)


The Measures for Compulsory License on Patent Implementation concerning Public Health Problems, which were discussed and adopted at the executive meeting of the State Intellectual Property Office, are hereby promulgated, and shall come into force as of January 1, 2006.
 
《涉及公共健康问题的专利实施强制许可办法》已经局务会议审议通过,现予公布,自2006年1月1日起施行。

Director General Tian Lipu
 
局长 田力普

November 29, 2005
 
二00五年十一月二十九日

Measures for Compulsory License on Patent Implementation concerning Public Health Problems
 

涉及公共健康问题的专利实施强制许可办法


   第一条 为了解决我国面临的公共健康问题,并帮助有关国家、地区解决其面临的公共健康问题,落实世界贸易组织多哈部长级会议《关于TRIPS协议与公共健康的宣言》(下称“多哈宣言”)和世界贸易组织总理事会《关于实施TRIPS协议与公共健康的多哈宣言第6段的决议》(下称“总理事会决议”),根据《中华人民共和国专利法》(下称“专利法”),制定本办法。
Article 1 With a view to solving public health problems faced by our country, and helping the relevant states and districts solve the public health problems they face, and implementing the Doha Declaration on TRIPS and Public Health (hereinafter called as the “Doha Declaration”) by the WTO Ministerial Conference in Doha and the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS and Public Health (hereinafter called as the Resolutions of the General Council) by the General Council of WTO, the present Measures are formulated in accordance with the Patent Law of the People's Republic of China (hereinafter called as the “Patent Law”). 

   第二条 本办法所称传染病,是指导致公共健康问题的艾滋病、肺结核、疟疾以及《中华人民共和国传染病防治法》规定的其他传染病。
Article 2 The epidemic diseases as mentioned in the present Measures shall refer to HIV/AIDS, tuberculosis, malaria, which result in public health problems, and other epidemics as prescribed in the Law of the People's Republic of China on the Prevention and Control of Epidemic Diseases. 
本办法所称药品,是指在医药领域用于治疗本条第一款所述传染病的任何专利产品或者通过专利方法制造的产品,包括制造前述产品所需的有效成分和使用前述产品所需的诊断试剂。

The medicines as mentioned in the present Measures shall refer to any patent product or product produced through patented process in the medical field for the treatment of the epidemic diseases as mentioned in paragraph one of this Article, including the effective components needed for the manufacture of the aforesaid products and the diagnosis reagents needed when using the aforesaid products.
 

   第三条 在我国预防或者控制传染病的出现、流行,以及治疗传染病,属于专利法四十九条所述为了公共利益目的的行为。
......

Dear visitor, as a premium member of this database, you will get complete access to all content.Please go premium and get more.

1. To become a premium member, please call 400-810-8266 Ext. 171.

2. Binding to the account with access to this database.

3. Apply for a trial account.

4. To get instant access to a document, you can Pay Amount 【¥200.00】 for your single purchase.
 
您好:您现在要进入的是北大法宝英文库会员专区。
如您是我们英文用户可直接 登录,进入会员专区查询您所需要的信息;如您还不是我们 的英文用户;您可通过网上支付进行单篇购买,支付成功后即可立即查看本篇内容。
Tel: +86 (10) 82689699, +86 (10) 82668266 ext. 153
Mobile: +86 13311570713
Fax: +86 (10) 82668268
E-mail:info@chinalawinfo.com
     
     
Scan QR Code and Read on Mobile
【法宝引证码】        北大法宝en.pkulaw.cn
Message: Please kindly comment on the present translation.
Confirmation Code:
Click image to reset code
 
  Translations are by lawinfochina.com, and we retain exclusive copyright over content found on our website except for content we publish as authorized by respective copyright owners or content that is publicly available from government sources.

Due to differences in language, legal systems, and culture, English translations of Chinese law are for reference purposes only. Please use the official Chinese-language versions as the final authority. Lawinfochina.com and its staff will not be directly or indirectly liable for use of materials found on this website.

We welcome your comments and suggestions, which assist us in continuing to improve the quality of our materials as we dynamically expand content.
 
Home | About us | Disclaimer | Chinese